569 related articles for article (PubMed ID: 26660203)
1. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.
Ramiro S; Smolen JS; Landewé R; van der Heijde D; Dougados M; Emery P; de Wit M; Cutolo M; Oliver S; Gossec L
Ann Rheum Dis; 2016 Mar; 75(3):490-8. PubMed ID: 26660203
[TBL] [Abstract][Full Text] [Related]
2. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Ferreira RJO; Bertheussen H; Baraliakos X; Aletaha D; McGonagle DG; van der Heijde D; McInnes IB; Esbensen BA; Winthrop KL; Boehncke WH; Schoones JW; Gossec L
Ann Rheum Dis; 2024 May; 83(6):760-774. PubMed ID: 38503473
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
[TBL] [Abstract][Full Text] [Related]
9. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
Ash Z; Gaujoux-Viala C; Gossec L; Hensor EM; FitzGerald O; Winthrop K; van der Heijde D; Emery P; Smolen JS; Marzo-Ortega H
Ann Rheum Dis; 2012 Mar; 71(3):319-26. PubMed ID: 21803753
[TBL] [Abstract][Full Text] [Related]
10. Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis.
Paccou J; Wendling D
Joint Bone Spine; 2015 Mar; 82(2):80-5. PubMed ID: 24997741
[TBL] [Abstract][Full Text] [Related]
11. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS
Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672
[TBL] [Abstract][Full Text] [Related]
12. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
13. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Gossec L; Baraliakos X; Kerschbaumer A; de Wit M; McInnes I; Dougados M; Primdahl J; McGonagle DG; Aletaha D; Balanescu A; Balint PV; Bertheussen H; Boehncke WH; Burmester GR; Canete JD; Damjanov NS; Kragstrup TW; Kvien TK; Landewé RBM; Lories RJU; Marzo-Ortega H; Poddubnyy D; Rodrigues Manica SA; Schett G; Veale DJ; Van den Bosch FE; van der Heijde D; Smolen JS
Ann Rheum Dis; 2020 Jun; 79(6):700-712. PubMed ID: 32434812
[TBL] [Abstract][Full Text] [Related]
14. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
[TBL] [Abstract][Full Text] [Related]
19. Treatment of psoriatic arthritis: management recommendations.
Gossec L; Smolen JS
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S73-7. PubMed ID: 26471459
[TBL] [Abstract][Full Text] [Related]
20. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
